NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENO-60 is a diatrizoate meglumine injectable contrast agent used in diagnostic imaging procedures to enhance visualization of internal body structures. It is administered via injection and works by absorbing X-rays to create contrast in radiographic imaging. This is a small-molecule contrast medium with decades of clinical use in radiology.
LOE Approaching
With LOE approaching and high competitive pressure (30%), the brand team is likely transitioning to defensive positioning and cost-optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities tied to RENO-60 are minimal, with zero linked job openings currently identified. Working on this product typically involves defensive commercial strategy, legacy account management, and margin protection rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on RENO-60 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.